SCHEMBL3633876

SCHEMBL3633876

CCCC(=O)c1ccc(NCc2cn(C)cn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC27A1 Q6PCB7 2/20 0.44
METTL3 Q86U44 1/20 0.42
FRK P42685 1/20 0.42
CAMK2B Q13554 1/20 0.42
CAMK2G Q13555 1/20 0.42
CAMK2D Q13557 1/20 0.42
HSD17B3 P37058 1/20 0.42
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGDS O60760 1/20 0.38
OGA O60502 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR1D P28221 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3637892 0.78 SLC27A1 (0.44) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3635224 0.76 MAOA (0.56) SLC27A1HPGDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3637505 0.76 SMN1; SMN2 (0.44) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3638167 0.75 KDM4C (0.44) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3638724 0.74 FRK (0.44) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3640996 0.74 TRPM5 (0.46) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3640387 0.74 FRK (0.44) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3635307 0.73 RAB9A (0.49) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3639351 0.73 FRK (0.43) SLC27A1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3732110 0.73 ALDH1A1 (0.62) SLC27A1HPGDSMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 SLC27A1 872/4885METTL3 3048/4885FRK 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.